XML 50 R40.htm IDEA: XBRL DOCUMENT v3.19.2
Asterias Merger (Details Narrative) - USD ($)
$ / shares in Units, $ in Thousands
1 Months Ended 3 Months Ended 6 Months Ended
Mar. 31, 2019
Mar. 08, 2019
Mar. 08, 2019
Apr. 30, 2019
Sep. 30, 2018
Jun. 30, 2019
Jun. 30, 2019
Jun. 30, 2018
Dec. 31, 2018
May 13, 2016
Closing price of common stock           $ 133,387 $ 133,387   $ 93,840  
Number of warrants issued to purchase of common stock                   2,813,159
Fair value of warrants       $ 372     (271) $ (351)    
Common stock held in investment   2,621,811 2,621,811              
Share price, per share   $ 1.31 $ 1.31           $ 0.62  
Fair value of equity method investment, shares 21,700,000                  
Fair value of equity method investment, value   $ 20,200 $ 20,200           $ 13,500  
Fair value calculation, description   The fair value of the Asterias shares was approximately $20.2 million as of March 8, 2019, the closing date of the Asterias Merger, based on $0.93 per share, which was calculated by multiplying (a) $1.31, the closing price of BioTime common stock on such date by (b) the Merger Exchange Ratio.                
General and Administrative [Member]                    
Acquisition related costs           $ 900 $ 4,400      
Common Stock [Member]                    
Number of warrants issued to purchase of common stock                   2,959,559
Exercise price                   $ 4.37
Warrant term                   5 years
Warrant expiration date                   May 13, 2021
BioTime Warrants [Member]                    
Exercise price           $ 6.15 $ 6.15      
Warrant expiration date           May 13, 2021 May 13, 2021      
Fair value of warrants $ 495                  
AST Clinical Program [Member]                    
Identifiable intangible asset acquired   $ 46,500                
Royalty Contracts [Member]                    
Useful life of asset             5 years      
In Process Research and Development [Member]                    
Identifiable intangible asset acquired   31,700                
Regenerative Medicine [Member]                    
Identifiable intangible asset acquired   $ 14,800                
December 31, 2018 to March 8, 2019 [Member]                    
Unrealized loss             $ 6,700      
December 31, 2017 to June 30, 2018 [Member]                    
Unrealized loss               $ 19,600    
December 31, 2017 to June 30, 2018 [Member] | Maximum [Member]                    
Share price, per share               $ 2.25    
December 31, 2017 to June 30, 2018 [Member] | Minimum [Member]                    
Share price, per share               $ 1.35    
Parent Company [Member]                    
Number of warrants issued to purchase of common stock           1,089,900 1,089,900      
Fair value of warrants       $ 332            
Exchange of shares       251,835            
Exchange for cash       $ 40            
Asterias [Member]                    
Upfront payment received         $ 1,000          
Estimated purchase price         $ 200          
Merger Consideration [Member] | Parent Company [Member]                    
Stock-for-stock transaction   24,695,898 24,695,898              
Closing price of common stock   $ 32,400 $ 32,400              
Merger Consideration [Member] | Asterias [Member]                    
Stock-for-stock transaction   0.71 0.71              
Merger Consideration [Member] | Asterias [Member] | Restricted Stock [Member]                    
Stock-for-stock transaction   58,085 58,085